Press release content from Accesswire. The AP news staff was not involved in its creation.
Core One Labs Announces Its Entrance into the Ketamine Space with Proposed Acquisition of Ketamine Infusion Centers of Texas
February 4, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / February 4, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the “Company”) a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a letter of intent (the “Letter of Intent”) dated January 20, 2021 with Ketamine Infusion Centers of Texas, LLC (“KICT”), an arms-length-party, to review a potential acquisition of KICT.
IRW-News: Core One Labs Inc : Core One Labs kündigt seinen Einstieg in den Ketamin-Markt mit der geplanten Übernahme von Ketamine Infusion Centers of Texas an
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
Core One Labs Announces Vocan Assembles Equipment to Produce Biosynthesized Psilocybin
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Core One Labs Inc.: Core One Labs Announces Vocan Assembles Equipment to Produce Biosynthesized Psilocybin
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the
Company ) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (
Vocan ) has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin. The process that engineers bacteria incorporating optimized biosynthetic genes from the
Psilocybe cubensis mushroom, will enable the bacteria to act as a biological factory and synthesize psilocybin that is cost effective using simple building blocks.
Vocan s platform can make the active compounds that occur naturally, by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds as well as known and novel analogs. The analog compounds could prove to be more effective, targeted and safer.